Table 2.

Activities of pCRP and mCRP with various Cancer models.

Cancer Type	CRP Reagent Used	Mechanistic Notes	References
Melanoma	Isolated CRP	72 hr. growth in tissue culture Added with lymphocytes Stopped growth of tumor cells	➢ (28)
Fibrosarcoma	CRP encapsulated in liposomes	Anti-metastatic, especially when injected early in disease course Non-encapsulated CRP was not similary effective	➢ (29)
Melanoma Fibrosarcoma Sarcoma	CRP encapsulated in liposomes	Showed tumoricidal activity Anti-tumor response found in exudate macrophages and involved enhanced oxidate metabolism	➢ (30)
Colon Adenocarcinoma	CRP encapsulated in liposomes	Treatment resulted in fewer and smaller liver metastases	➢ (31)
Fibrosarcoma Colon carcinoma	CRP encapsulated in liposomes	Stimulated peritoneal, exudate cells Required an intact complement system	➢ (32) ➢ (33)
Mastocytoma Fibroblast carcinoma CAK-1 (mesothelial & ovarian) carcinomas	Isolated CRP Heat aggregated CRP lost tumoricidal activity	CRP added to tissue cultured cells CRP affect did not involve lymphokines CRP-activated macrophages did not affect normal fibroblast	➢ (34)
Astrocytoma Renal carcinoma Melanoma	Isolate CRP	CRP activated peripheral blood mononuclear cells (PBMs) but required incubation on glass–adherent cells for 20-44 hr. Tumoricidal activity involved superoxide anion generation Normal PBMs were similarly activated by CRP but normal fibroblasts and glial cells were not	➢ (35, 36)
Fibrosarcoma	Peptides derived from CRP in liposomes	Identified a peptide with anti-tumor and anti-lung metastatic activity Peptide 174IYLGGPFSPNVL185 Stimulated Peripheral blood MAC 1+ (CR3+) cells Required encapsulated in a liposome	➢ (37, 38)
Fibrosarcoma	CRP encapsulated in liposome CRP-peptide encapsulated in liposomes	Increased IL-1 and TNF secretion from monocytes and alveolar macrophages When IL-2 was co-administered with CRP regeant, reported enhanced Influenced IL-1-β, IL-6 and TNF-α secretion on cultured monocytes	➢ (39–41) ➢ (42) ➢ (43)
Breast Adenocarcinoma	mCRP in LUVETS CRP in LUVETs Isolated pCRP Isolated mCRP	mCRP alone or in LUVETS slowed tumor growth, caused necrosis at site of tumor growth and reduced metastasis pCRP alone or in LUVETS was ineffective in slowing tumor growth or preventing metastasis	➢ (44, 45)
Lewis Lung Carcinoma CAPAN-2 Pancreatic	mCRP Recombinant nCRP	Slower tumor growth Cased necrosis at tumor site Anti-cancer effects observed in nude mice	➢ See Supplementary Figure 2 ➢ (8)